SK18295A3 - 3- and 5-substituted 1,2,3,4-oxatriazole -5-imine compounds, method of their preparation, pharmaceutical agent containing these compounds and their use for prepare of medicine - Google Patents

3- and 5-substituted 1,2,3,4-oxatriazole -5-imine compounds, method of their preparation, pharmaceutical agent containing these compounds and their use for prepare of medicine Download PDF

Info

Publication number: SK18295A3
Authority: SK; Slovakia
Prior art keywords: oxatriazole; alkyl; formula; substituted; aryl
Prior art date: 1992-08-10

Application number

SK182-95A

Other languages

English (en)

Slovak (sk)

Inventor

Gunnar L Karup

Herbert F Preikschat

Soren B Pedersen

Tim N Corell

Borge I F Alhede

Original Assignee

Gea Farmaceutisk Fabrik As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-10

Filing date

1993-07-08

Publication date

1995-07-11

1993-07-08 Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As

1995-07-11 Publication of SK18295A3 publication Critical patent/SK18295A3/sk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 39
-1 5-substituted 1,2,3,4-oxatriazole Chemical class 0.000 title claims abstract description 32
238000002360 preparation method Methods 0.000 title claims description 13
239000003814 drug Substances 0.000 title claims description 7
238000000034 method Methods 0.000 title claims description 7
239000008177 pharmaceutical agent Substances 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
QPTISOPQFLIZCY-UHFFFAOYSA-N oxatriazol-5-amine Chemical class NC1=NN=NO1 QPTISOPQFLIZCY-UHFFFAOYSA-N 0.000 claims abstract description 11
125000003118 aryl group Chemical group 0.000 claims abstract description 10
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 5
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
150000002367 halogens Chemical class 0.000 claims abstract description 4
230000002378 acidificating effect Effects 0.000 claims abstract description 3
150000003839 salts Chemical class 0.000 claims abstract description 3
229910052799 carbon Inorganic materials 0.000 claims description 19
150000002466 imines Chemical class 0.000 claims description 13
208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 7
208000006673 asthma Diseases 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
201000001881 impotence Diseases 0.000 claims 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 abstract description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
239000000203 mixture Substances 0.000 description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
238000003756 stirring Methods 0.000 description 23
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
238000001914 filtration Methods 0.000 description 16
239000002244 precipitate Substances 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
230000008018 melting Effects 0.000 description 12
238000002844 melting Methods 0.000 description 12
229910052757 nitrogen Inorganic materials 0.000 description 12
QFGLIIGBBQLMOS-UHFFFAOYSA-N 3-(3-chloro-2-methylphenyl)-2h-oxatriazol-2-ium-5-amine;chloride Chemical compound Cl.CC1=C(Cl)C=CC=C1N1NC(=N)ON1 QFGLIIGBBQLMOS-UHFFFAOYSA-N 0.000 description 11
239000000047 product Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000000921 elemental analysis Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000001569 carbon dioxide Substances 0.000 description 8
229910002092 carbon dioxide Inorganic materials 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
210000000056 organ Anatomy 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
230000002776 aggregation Effects 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
210000003437 trachea Anatomy 0.000 description 6
230000008602 contraction Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 4
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000002040 relaxant effect Effects 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000013558 reference substance Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
UGFVODHLEUQXMH-UHFFFAOYSA-N (3-chloro-2-methylanilino)thiourea Chemical compound CC1=C(Cl)C=CC=C1NNC(N)=S UGFVODHLEUQXMH-UHFFFAOYSA-N 0.000 description 2
101710175576 Aggregation substance Proteins 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
125000005233 alkylalcohol group Chemical group 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
230000000361 pesticidal effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
230000000328 pro-aggregatory effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
229940083618 sodium nitroprusside Drugs 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
238000002834 transmittance Methods 0.000 description 2
NFVOTDWJCRXNTA-UHFFFAOYSA-N (3-chloro-2-methylphenyl)hydrazine;hydrochloride Chemical compound Cl.CC1=C(Cl)C=CC=C1NN NFVOTDWJCRXNTA-UHFFFAOYSA-N 0.000 description 1
DZMNKFGBWZJKRP-UHFFFAOYSA-N 3-phenyl-2h-oxatriazol-5-amine Chemical class N1OC(=N)NN1C1=CC=CC=C1 DZMNKFGBWZJKRP-UHFFFAOYSA-N 0.000 description 1
RGVBEISMHCYSNF-UHFFFAOYSA-N 4-methoxy-n-(oxomethylidene)benzenesulfonamide Chemical compound COC1=CC=C(S(=O)(=O)N=C=O)C=C1 RGVBEISMHCYSNF-UHFFFAOYSA-N 0.000 description 1
AWTJUYXVSWZCIK-UHFFFAOYSA-N 4-methyl-1,3-thiazole-5-sulfonyl chloride Chemical compound CC=1N=CSC=1S(Cl)(=O)=O AWTJUYXVSWZCIK-UHFFFAOYSA-N 0.000 description 1
101100203530 Caenorhabditis elegans stn-1 gene Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
LHLIGPDDSKJRQN-UHFFFAOYSA-N ethyl 2-isocyanato-3-phenylpropanoate Chemical compound CCOC(=O)C(N=C=O)CC1=CC=CC=C1 LHLIGPDDSKJRQN-UHFFFAOYSA-N 0.000 description 1
DUVOZUPPHBRJJO-UHFFFAOYSA-N ethyl 2-isocyanatoacetate Chemical compound CCOC(=O)CN=C=O DUVOZUPPHBRJJO-UHFFFAOYSA-N 0.000 description 1
XBSGYVHOINMTIM-UHFFFAOYSA-N ethyl 3-isocyanatopropanoate Chemical compound CCOC(=O)CCN=C=O XBSGYVHOINMTIM-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical class O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
UJYAZVSPFMJCLW-UHFFFAOYSA-N n-(oxomethylidene)benzenesulfonamide Chemical compound O=C=NS(=O)(=O)C1=CC=CC=C1 UJYAZVSPFMJCLW-UHFFFAOYSA-N 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical group C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000002541 vasodepressive effect Effects 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SK182-95A 1992-08-10 1993-07-08 3- and 5-substituted 1,2,3,4-oxatriazole -5-imine compounds, method of their preparation, pharmaceutical agent containing these compounds and their use for prepare of medicine SK18295A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK921003A DK100392D0 (da)	1992-08-10	1992-08-10	3- og 5-substituerede 1,2,3,4-oxatriazol-5-iminforbindelser og fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse forbindelser samt forbindelsernes anvendelse til fremstilling af laegemidler
PCT/DK1993/000234 WO1994003442A1 (en)	1992-08-10	1993-07-08	3- and 5-substituted 1,2,3,4-oxatriazole-5-imine compounds, a process for the preparation thereof, a pharmaceutical preparation containing said compounds and the use of said compounds for the preparation of medicaments

Publications (1)

Publication Number	Publication Date
SK18295A3 true SK18295A3 (en)	1995-07-11

Family

ID=8099920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK182-95A SK18295A3 (en)	1992-08-10	1993-07-08	3- and 5-substituted 1,2,3,4-oxatriazole -5-imine compounds, method of their preparation, pharmaceutical agent containing these compounds and their use for prepare of medicine

Country Status (29)

Country	Link
EP (1)	EP0654028B1 (is)
JP (1)	JPH07509703A (is)
CN (1)	CN1086813A (is)
AP (1)	AP455A (is)
AT (1)	ATE136893T1 (is)
AU (1)	AU4418193A (is)
BG (1)	BG99378A (is)
BR (1)	BR9306880A (is)
CA (1)	CA2140641A1 (is)
CZ (1)	CZ33995A3 (is)
DE (1)	DE69302279T2 (is)
DK (2)	DK100392D0 (is)
EE (1)	EE9400084A (is)
ES (1)	ES2085787T3 (is)
FI (1)	FI950575A0 (is)
GR (1)	GR3019681T3 (is)
HU (1)	HUT71230A (is)
IS (1)	IS4052A (is)
LT (1)	LT3054B (is)
LV (1)	LV10263B (is)
MX (1)	MX9304788A (is)
NZ (1)	NZ253681A (is)
OA (1)	OA10127A (is)
PL (1)	PL307395A1 (is)
RU (1)	RU95106464A (is)
SI (1)	SI9300425A (is)
SK (1)	SK18295A3 (is)
WO (1)	WO1994003442A1 (is)
ZA (1)	ZA935199B (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9504230A (es) *	1994-10-07	1997-03-29	Gea Farmaceutisk Fabrik As	Compuestos de 1,2,3,4-oxatriazol-5-imina sustituidos en las posiciones 3 y 5, proceso para la preparacion de los mismos, preparacion farmaceutica que contiene dichos compuestos y el uso de los mismos para la preparacion de medicamentos.
US6399618B1 (en)	1997-07-09	2002-06-04	Cardiome Pharma Corp	Compositions and methods for modulating sexual activity
FR2786699B1 (fr) *	1998-12-02	2002-10-04	Philippe Gorny	Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
CN111217817B (zh) *	2020-02-26	2022-06-10	山东潍坊润丰化工股份有限公司	一种三唑并嘧啶类除草剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2015878B (en)	1978-03-10	1982-05-26	Shell Int Research	Biocidal compositions
US4329355A (en) *	1979-03-01	1982-05-11	Henry David W	Mesoionic antitumor compositions and methods for using the same in the treatment of cancer

1992
- 1992-08-10 DK DK921003A patent/DK100392D0/da not_active Application Discontinuation
1993
- 1993-07-08 DE DE69302279T patent/DE69302279T2/de not_active Expired - Fee Related
- 1993-07-08 CZ CZ95339A patent/CZ33995A3/cs unknown
- 1993-07-08 AT AT93914656T patent/ATE136893T1/de active
- 1993-07-08 WO PCT/DK1993/000234 patent/WO1994003442A1/en not_active Ceased
- 1993-07-08 ES ES93914656T patent/ES2085787T3/es not_active Expired - Lifetime
- 1993-07-08 NZ NZ253681A patent/NZ253681A/en unknown
- 1993-07-08 PL PL93307395A patent/PL307395A1/xx unknown
- 1993-07-08 JP JP6504904A patent/JPH07509703A/ja active Pending
- 1993-07-08 RU RU95106464/04A patent/RU95106464A/ru unknown
- 1993-07-08 AU AU44181/93A patent/AU4418193A/en not_active Abandoned
- 1993-07-08 HU HU9500401A patent/HUT71230A/hu unknown
- 1993-07-08 CA CA002140641A patent/CA2140641A1/en not_active Abandoned
- 1993-07-08 EP EP93914656A patent/EP0654028B1/en not_active Expired - Lifetime
- 1993-07-08 BR BR9306880A patent/BR9306880A/pt not_active Application Discontinuation
- 1993-07-08 SK SK182-95A patent/SK18295A3/sk unknown
- 1993-07-08 DK DK93914656.9T patent/DK0654028T3/da active
- 1993-07-13 IS IS4052A patent/IS4052A/is unknown
- 1993-07-19 ZA ZA935199A patent/ZA935199B/xx unknown
- 1993-07-23 LT LTIP816A patent/LT3054B/lt not_active IP Right Cessation
- 1993-07-26 AP APAP/P/1993/000559A patent/AP455A/en active
- 1993-08-06 MX MX9304788A patent/MX9304788A/es not_active Application Discontinuation
- 1993-08-10 SI SI9300425A patent/SI9300425A/sl unknown
- 1993-08-10 CN CN93109277A patent/CN1086813A/zh active Pending
- 1993-08-10 LV LVP-93-1027A patent/LV10263B/en unknown
1994
- 1994-08-09 EE EE9400084A patent/EE9400084A/xx unknown
1995
- 1995-01-27 BG BG99378A patent/BG99378A/bg unknown
- 1995-02-09 FI FI950575A patent/FI950575A0/fi not_active Application Discontinuation
- 1995-02-10 OA OA60609A patent/OA10127A/en unknown
1996
- 1996-04-19 GR GR960401060T patent/GR3019681T3/el unknown

Also Published As

Publication number	Publication date
EP0654028B1 (en)	1996-04-17
DK0654028T3 (da)	1996-07-29
WO1994003442A1 (en)	1994-02-17
NZ253681A (en)	1995-09-26
LV10263A (lv)	1994-10-20
ATE136893T1 (de)	1996-05-15
DE69302279D1 (de)	1996-05-23
LTIP816A (en)	1994-05-15
PL307395A1 (en)	1995-05-15
AP455A (en)	1996-01-19
MX9304788A (es)	1994-02-28
EE9400084A (et)	1995-12-15
OA10127A (en)	1996-12-18
CA2140641A1 (en)	1994-02-17
LV10263B (en)	1995-06-20
SI9300425A (en)	1994-03-31
IS4052A (is)	1994-02-11
GR3019681T3 (en)	1996-07-31
CN1086813A (zh)	1994-05-18
EP0654028A1 (en)	1995-05-24
JPH07509703A (ja)	1995-10-26
CZ33995A3 (en)	1995-09-13
FI950575A7 (fi)	1995-02-09
DE69302279T2 (de)	1996-09-19
FI950575A0 (fi)	1995-02-09
DK100392D0 (da)	1992-08-10
HUT71230A (en)	1995-11-28
HU9500401D0 (en)	1995-03-28
RU95106464A (ru)	1996-12-27
AU4418193A (en)	1994-03-03
AP9300559A0 (en)	1993-10-31
BG99378A (bg)	1995-11-30
ZA935199B (en)	1994-03-02
ES2085787T3 (es)	1996-06-01
LT3054B (en)	1994-10-25
BR9306880A (pt)	1998-12-08

Publication	Publication Date	Title
SU1400508A3 (ru)	1988-05-30	Способ получени производных арилтиазолов
BRPI0709866A2 (pt)	2011-07-26	composto hÉtero
BRPI0707285A2 (pt)	2011-04-26	isoxazóis reversos
EP2906551A1 (en)	2015-08-19	Crystalline forms of a factor xia inhibitor
BRPI0619260A2 (pt)	2011-09-27	derivados de oxadiazol com atividade de receptor ctrh2, composição farmacêutica que os compreende e uso dos referidos derivados
WO2015024011A2 (en)	2015-02-19	Antibacterial compounds
Wuest et al.	1951	Some Derivatives of 3-Pyridol with Parasympathomimetic Properties1
CN113121521A (zh)	2021-07-16	6-位三氟甲基取代的苯并噻嗪酮衍生物及其制备方法与应用
SK18295A3 (en)	1995-07-11	3- and 5-substituted 1,2,3,4-oxatriazole -5-imine compounds, method of their preparation, pharmaceutical agent containing these compounds and their use for prepare of medicine
Akerblom et al.	1973	Nitrofuryltriazole derivatives as potential urinary tract antibacterial agents
JP2012505921A (ja)	2012-03-08	低酸素性損傷または虚血性損傷を治療しまたは予防するための組成物および方法
US5405857A (en)	1995-04-11	3-substituted 1,2,3,4,-oxatriazole-5-imine compounds, a process for the preparation thereof and a pharmaceutical preparation containing said compounds
CA1037475A (en)	1978-08-29	Lactam compounds and conjugates
ES2253315T3 (es)	2006-06-01	Analogos de fenoxacina para el tratamiento de amiloides.
JPS62108863A (ja)	1987-05-20	２−ピリジル酢酸誘導体、その製法およびそれを含む医薬
WO1996011191A1 (en)	1996-04-18	Substituted 3-phenyl-1,2,3,4-oxatriazole-5-imines useful for the treatment of asthma and thrombosis
Keglević et al.	1959	The Resolution of B-Amino-1-methylsulphinyl-butyric Acid (B-Methionine Sulphoxide) into Four Optical Isomers
Devi et al.	2019	Synthesis and Screening of 3-(4-Oxo-2-Phenyl-1, 3-Thiazol-5 (4h)-Ylidene)-1, 3-Dihydro-2h-Indol-2-One-N-Methylanilines for Antiinflammatory Activity
KR810001978B1 (ko)	1981-12-08	2, 5-디히드로-1, 2티아지노 [5, 6-b]인돌-3-카복사미드-1, 1-디옥사이드의제조 방법
JP2017521444A (ja)	2017-08-03	ピラゾロン化合物およびその使用
Devi et al.	2019	Synthesis and Screening of 3-(4-Oxo-2-Phenyl-1, 3-Thiazol-5 (4H)-Ylidene)-1, 3-Dihydro-2H-Indol-2-One-N-Methylanilines for in vivo Antiinflammatory Activity
JPS59104378A (ja)	1984-06-16	カルボスチリル誘導体
HRP920895A2 (en)	1994-12-31	3-substituted 1,2,3,4-oxatriazole-5-imine compounds, a process for the preparation thereof and a pharmaceutical preparation containing the said compounds
CA2916805A1 (en)	2015-01-08	N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-(trifluoromethylsulfanyl)benzamide derivatives for use as nematocidal drugs
JPS6133115A (ja)	1986-02-17	ヒドロキサム酸含有薬剤